Related Experiment Videos
[Chronic osteomyelitis: a new therapeutical idea]
G. Carlino1, P. Trande, M. Muratore
1A.U.S.L. LE/02, Maglie, Lecce; Italia. giorgiocarlino@medicitalia.it
Abstract:
We studied the case of a male patient aged 43 affected by post-traumatic chronic osteomyelitis with frequent relapses. Having supposed an insufficiency of the arterial and venous microcirculation in perilesional bone and soft tissue we decided for a therapy with iloprost and antibacterial drugs. After 15 months of treatment the patient hasn't showed any clinically evident relapsing episodes and we have not reported any side effects related to the therapy.
Insights
This study investigated iloprost and antibacterial therapy for chronic osteomyelitis. The treatment successfully prevented relapses and showed no side effects in a 43-year-old male patient over 15 months.
Area of Science:
- Orthopedics
- Vascular Medicine
- Infectious Diseases
Background:
- Chronic osteomyelitis is a persistent bone infection often characterized by frequent relapses.
- Microcirculatory insufficiency in bone and soft tissue may contribute to treatment resistance and recurrence.
- Post-traumatic osteomyelitis presents unique challenges due to associated tissue damage.
Purpose of the Study:
- To evaluate the efficacy of iloprost combined with antibacterial drugs in managing chronic osteomyelitis.
- To investigate the role of microcirculation improvement in treating refractory osteomyelitis.
- To assess the safety and tolerability of this combined therapeutic approach.
Main Methods:
- A case study of a 43-year-old male patient with recurrent post-traumatic chronic osteomyelitis.
- Therapeutic intervention involving iloprost (a prostaglandin analog) and targeted antibacterial agents.
- Monitoring for clinical relapse and adverse events over a 15-month follow-up period.
Main Results:
- The patient experienced no clinically evident relapses of osteomyelitis during the 15-month treatment period.
- No adverse side effects attributable to iloprost or antibacterial therapy were reported.
- The treatment regimen appeared effective in managing the chronic infection.
Conclusions:
- Combined therapy with iloprost and antibacterial drugs shows promise for treating chronic osteomyelitis with microcirculatory compromise.
- Iloprost may improve outcomes by enhancing vascularity in affected tissues.
- This approach offers a potential strategy for preventing relapses in challenging osteomyelitis cases.